clinical trial · NCT05763459
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
HealthyABBV-CLS-7262
brief summary
This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262
started
Mar 24, 2023
primary completion
May 8, 2023
completion
Jun 2, 2023
last updated
Jun 26, 2023
detailed description
Period 1: One single dose of rosuvastatin and one single dose of digoxin on Day 1.
Period 2: Multiple doses of ABBV-CLS-7262 once daily from Day 1 to Day 8. On Day 5, one single dose of rosuvastatin and one single dose of digoxin with the dose of ABBV-CLS-7262 on that day.
official title
A Phase 1 Study to Evaluate the Drug-Drug Interaction Between ABBV-CLS-7262, Rosuvastatin, and Digoxin Following Multiple Doses of ABBV-CLS-7262
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol